Nonfunctioning neuroendocrine pancreatic tumors: Our experience and management

Journal of Hepato-Biliary-Pancreatic Surgery

Volumn 16, Issue 5, 2009, Pages 639-647

  Nomura, Naohiro ^a   Fujii, Tsutomu ^a   Kanazumi, Naohito ^a   Takeda, Shin ^a   Nomoto, Shuji ^a   Kasuya, Hideki ^a   Sugimoto, Hiroyuki ^a   Yamada, Suguru ^a   Nakao, Akimasa ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Nonfunctioning neuroendocrine tumor; Pancreas; WHO classification

Indexed keywords

DACARBAZINE; EPIRUBICIN; FLUOROURACIL; MITOMYCIN C;

ABDOMINAL PAIN; ADRENAL METASTASIS; ADRENALECTOMY; ADULT; AGED; ALOPECIA; ARTICLE; BENIGN TUMOR; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL ARTICLE; FEMALE; HEMICOLECTOMY; HUMAN; KIDNEY METASTASIS; LIVER METASTASIS; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MALE; MALIGNANT NEOPLASTIC DISEASE; NAUSEA; NEOPLASMS OF UNCERTAIN BEHAVIOR; NEPHRECTOMY; NEUROENDOCRINE TUMOR; NEUTROPENIA; NONFUNCTIONING NEUROENDOCRINE PANCREAS TUMOR; OBSTRUCTIVE JAUNDICE; PANCREAS RESECTION; PANCREATICODUODENECTOMY; PROGNOSIS; RADIOFREQUENCY ABLATION; SPLENECTOMY; SURVIVAL RATE; TUMOR CLASSIFICATION; TUMOR VOLUME; VOMITING;

ADULT; AGED; BIOPSY, NEEDLE; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEUROENDOCRINE TUMORS; PANCREATECTOMY; PANCREATIC NEOPLASMS; PROBABILITY; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 70049091797     PISSN: 09441166     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00534-009-0099-1     Document Type: Article

References (32)

1. Moldow RE, Conelly RR. Epidemiology of pancreatic cancer in Connecticut. Gastroenterology. 1968;55:677-86.
2. Kent RB, van Heerden JA, Weiland LH. Nonfunctioning islet cell tumors. Ann Surg. 1981;193:185-90.
3. Broughan TA, Leslie JD, Soto JM, Hermann RE. Pancreatic islet tumors. Surgery. 1986;99:671-8.
4. Capella C, Heitz PU, Höfler H, Solcia E, Klöppel G. Revised classification of neuroendocrine tumors of the lung, pancreas and gut. Virchows Arch. 1995;425:547-60.
5. Klöppel G, Heitz PU. Pancreatic endocrine tumors. Pathol Res Prac. 1998;183:155-68.
6. DeLellis RA, Lloyd RV, Heitz PU, Eng C. Tumours of the endocrine organs. WHO classification of tumors. Lyon: IARC Press; 2004.
7. La Rosa S, Sessa F, Capella C, Riva C, Leone BE, Klersy C, et al. Prognostic criteria in nonfunctioning pancreatic endocrine tumours. Virchows Arch. 1996;429:323-33.
8. Evans DB, Skibber JM, Lee JE, Cleary KR, Ajani JA, Gagel RF, et al. Nonfunctioning islet cell carcinoma of the pancreas. Surgery. 1993;114:1175-82.
9. Gullo L, Migliori M, Falconi M, Pederzoli P, Bettini R, Casadei R, et al. Nonfunctional pancreatic endocrine tumors: A multicenter clinical study. Am J Gastroenterol. 2003;98:2435-9.
10. Nakao A. Pancreatic head resection with segmental duodenectomy and preservation of the gastroduodenal artery. Hepatogastroenterology. 1998;45:533-5.
11. Procacci C, Carbognin G, Accordini S, Biasiutti C, Bicego E, Romano L, et al. Nonfunctional endocrine tumors of the pancreas: Possibilities of spiral CT characterization. Eur Radiol. 2001;11:1175-83.
12. Sugiyama M, Abe N, Izumisato Y, Yamaguchi Y, Yamato T, Tokuhara M, et al. Differential diagnosis of benign versus malignant nonfunctioning islet cell tumors of the pancreas: The roles of EUS and ERCP. Gastrointest Endosc. 2002;55:115-9.
13. Klöppel G, Schroder S, Heitz PU. Histopathology and immunopathology of the pancreatic endocrine tumors. In: Mignon M, Jensen RT, editors. Endocrine tumors of the pancreas. Recent advances in research and management. Basel: Karger; 1995. p. 99-120.
14. Madeira I, Terris B, Voss M, Denys A, Sauvanet A, Flejou JF, et al. Prognostic factors in patients with endocrine tumours of the duodenopancreatic area. Gut. 1998;43:422-7.
15. Dralle H, Krohn SL, Karges W, Boehm BO, Brauckhoff M, Gimm O. Surgery of resectable nonfunctioning neuroendocrine pancreatic tumors. World J Surg. 2004;28:1248-60.
16. Bartch DK, Langer P, Wild A, Schilling T, Celik I, Rothmund M, et al. Pancreaticoduodenal endocrine tumors in multiple endocrine neoplasia type 1: Surgery or surveillance? Surgery. 2000;128:958-66.
17. Solorzano CC, Lee JE, Pisters PWT, Vauthey JN, Ayers GD, Jean ME, et al. Nonfunctioning islet cell carcinoma of the pancreas: Survival results in a contemporary series of 163 patients. Surgery. 2001;130:1078-85.
18. Touzios JG, Kiely JM, Pitt SC, Rilling WS, Quebbeman EJ, Wilson SD, et al. Neuroendocrine hepatic metastases: Does aggressive management improve survival? Ann Surg. 2005;241:776-85.
19. Norton JA, Warren RS, Kelly MG, Zuraek MB, Jensen RT. Aggressive surgery for metastatic liver neuroendocrine tumors. Surgery. 2003;134:1057-65.
20. Elias D, Lasser P, Ducreux M, Duvillard P, Ouellet JF, Dromain C, et al. Liver resection (and associated extrahepatic resections) for metastatic well-differentiated endocrine tumors: A 15-year single center prospective study. Surgery. 2003;133:375-82.
21. Sarmiento JM, Heywood G, Rubin J, Ilstrup DM, Nagorney DM, Que FG. Surgical treatment of neuroendocrine metastases to the liver: A plea for resection to increase survival. J Am Coll Surg. 2003;197:29-37.
22. McEntee GP, Nagorney DM, Kvols LK, Moertel CG, Grant CS. Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery. 1990;108:1091-6.
23. Musunuru S, Chen H, Rajpal S, Stephani N, McDermott JC, Holen K, et al. Metastatic neuroendocrine hepatic tumors: Resection improves survival. Arch Surg. 2006;141:1000-4.
24. Ho AS, Picus J, Darcy MD, Gould JE, Pilgram TK, Brown DB. Long-term outcome after chemoembolization and embolization of hepatic metastatic lesions from neuroendocrine tumors. Am J Roentgenol. 2007;188:1201-7.
25. Wessels FJ, Schell SR. Radiofrequency ablation treatment of refractory carcinoid hepatic metastases. J Surg Res. 2001;95:8-12.
26. Moertel CG, Lefkopould M, Lipsitz S, Hahn RG. Streptozocin-doxorubicin, streptozocin-fluorouracil, or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med. 1992;326:519-23.
27. Ramanathan RK, Cnaan A, Hahn RG, Carbone PP, Haller DG. Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282. Ann Oncol. 2001;12:1139-43.
28. Arnold R, Rinke A, Schmidt Ch, Hofbauer L. Endocrine tumors of the gastrointestinal tract: Chemotherapy. Best Pract Res Clin Gastroenterol. 2005;19:649-56.
29. Bajetta E, Rimassa L, Carnaghi C, Seregni E, Ferrari L, Bartolomeo M, et al. 5-fluorouracil, dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors. Cancer. 1998;83:372-8.
30. Saltz L, Trochanowski B, Buckley M, Heffernan B, Niedzwiecki D, Tao Y, et al. Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors. Cancer. 1993;72:244-8.
31. Di Bartolomeo M, Bajetta E, Buzzoni R, Mariani L, Carnaghi C, Somma L, et al. ITMO Association. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. Cancer. 1996;77:402-8.
32. Fjällskog ML, Sundin A, Westlin JE, Öberg K, Janson ET, Eriksson B. Treatment of malignant endocrine pancreatic tumors with a combination of alpha-interferon and somatostatin analogs. Med Oncol. 2002;19:35-42.